Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 14Mesothelioma 10Retinoblastoma 6Unspecified Adult Solid Tumor, Protocol Specific 3Solid Tumors 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Pancreatic Neoplasms 2Osteosarcoma 2Medulloblastoma 2Malignant Solid Neoplasm 2Hematopoietic and Lymphatic System Neoplasm 2Esophageal Neoplasms 2Choroid Plexus Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Bile Duct Neoplasms 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thymoma 1Thrombocythemia, Essential 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Solitary Fibrous Tumor, Pleural 1

Interventions

sintilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × MSI-H × Other solid neoplasm × Clear all
NCT05890742 2026-05-28

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Active not recruiting
453 enrolled
Other solid neoplasm

MSI-H

Data powered by HemOnc (CC BY 4.0) Colophon âš¡